Genfit S.A. Genfit S.A.

Genfit S.A.

GNFT

Rank in Stocks #11141
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its... Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
Share Price
$12.02
Last synced: 2026-11-12
Market Cap
$603.98M
Change (1 day)
-1.58%
Change (1 year)
175.03%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Genfit S.A. (GNFT)
EPS as of June 2026 TTM: $-2.25
According to Genfit S.A.'s latest financial reports, its current EPS (TTM) is $-2.25. At the end of 2025 the company had an EPS of $-2.02, a decrease compared to its 2024 EPS of $0.03.
EPS history for Genfit S.A. from 2004 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-2.25 11.33%
2025 $-2.02 -6,567.95%
2024 $0.03 -104.87%
2023 $-0.64 24.53%
2022 $-0.51 -129.99%
2021 $1.72 -154.23%
2020 $-3.17 60.35%
2019 $-1.97 -32.61%
2018 $-2.93 29.90%
2017 $-2.26 67.49%
2016 $-1.35 79.77%
2015 $-0.75 -18.53%
2014 $-0.92 2.88%
2013 $-0.89 93.61%
2012 $-0.46 -52.45%
2011 $-0.97 -6.89%
2010 $-1.04 15.44%
2009 $-0.90 90.65%
2008 $-0.47 35.06%
2007 $-0.35 -1,045.55%
2006 $0.04 -79.06%
2005 $0.18 -40.60%
2004 $0.30 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -60.42%
US
$15.66 -796.37%
US
$-7.07 214.39%
US
$-5.29 135.24%
AU
$12.73 -666.18%
BE

Questions about Genfit S.A.'s earnings per share (EPS)

What is Genfit S.A.'s earnings per share (EPS)?

Genfit S.A.'s earnings per share (EPS) over the last twelve months is $-2.25, as of Jun 2026.

What was Genfit S.A.'s earnings per share (EPS) in 2025?

In 2025, Genfit S.A.'s earnings per share (EPS) was $-2.02, compared with $0.03 in 2024.

How has Genfit S.A.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Genfit S.A.'s earnings per share (EPS) was highest in 2021 ($1.72) and lowest in 2020 ($-3.17).

How does Genfit S.A.'s earnings per share (EPS) compare with similar companies?

Genfit S.A.'s earnings per share (EPS) ($-2.25) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.